Die Suchmaschine für Unternehmensdaten in Europa

EU-Förderung (14 Mio. €): Translational Safety Biomarker Pipeline (TransBioLine): Entwicklung und Umsetzung neuartiger Sicherheitsbiomarker in klinischen Studien und Diagnose von Krankheiten Hor 01.02.2019 EU-Rahmenprogramm für Forschung und Innovation "Horizont"

Auf einen Blick

Text

Translational Safety Biomarker Pipeline (TransBioLine): Entwicklung und Umsetzung neuartiger Sicherheitsbiomarker in klinischen Studien und Diagnose von Krankheiten

Qualified biomarkers help to optimize drug development and patient safety, yet for the regulatory acceptance of safety biomarkers substantial sample sizes are needed to ensure adequate case and control numbers, and robust evidence sufficient for qualification. To address this challenge, a consortium of leading European research institutions and SMEs has been established. The consortium will generate exploratory and confirmatory data enabling regulatory qualification of new safety biomarkers for application in drug development; establish robust datasets on the DILI, DIKI, DIPI, DIVI and DINI biomarkers to enhance diagnosis of disease; develop and validate assays for new safety biomarkers; implement profiles of circulating miRNAs as tissue and mechanism specific diagnostic tool; have key safety biomarkers accepted as qualified drug development tools by EMA, FDA, and PMDA. Given the significant expertise available across the consortium, the group will be able to tackle the key challenges related to successful biomarker qualification. A key driving principle of the consortium is cross-linking via existing networks of top profile research institutions, as well as capitalizing on existing data and resources. The Consortium is embedded into a network of international research collaborations such as the Pro-Euro-DILI-registry, TransQST, eTRANSAFE, the i2b2 tranSMART Foundation, the CIOMS DILI working group, EPoS, LITMUS, and BBMRI. To optimize regulatory interaction, we intend to continue our successful collaboration with non-European consortia such as PSTC, the FNIH Biomarkers Consortium, and US DILIN. A key expected result of the consortium will be a “Safety Biomarker Factory”, regularly qualifying new markers, with an associated “Safety Biomarker Warehouse”, providing to the scientific community, industry, and patients detailed data and information, and knowledge across a large spectrum of advanced safety biomarkers.


Geförderte Unternehmen:

Firmenname Förderungssumme
ABX CRO Advanced Pharmaceutical Services Forschungsgesellschaft mbH 1.294.360 €
Assistance Publique Hopitaux de Paris 34.000 €
Charite - Universitaetsmedizin Berlin 1.386.194 €
Eli Lilly and Company Ltd. 0,00 €
F. Hoffmann-LA Roche AG 0,00 €
Information Technology FOR Translational Medicine (Ittm) SA 624.125 €
Institut de Recerca de L'Hospital de La Santa Creu i Sant Pau Fundacion 182.600 €
Janssen Pharmaceutica N.V. 0,00 €
Landspitali University Hospital 87.325 €
Liverpool University Hospitals NHS Foundation Trust 0,00 €
Ludwig-Maximilians-Universitaet Muenchen 400.000 €
Merck Sharp & Dohme Corp 0,00 €
Metaheps GmbH 124.804 €
MLM Medical Labs GmbH 604.800 €
Novartis Pharma AG 0,00 €
Pfizer Ltd. 0,00 €
Sanofi-Aventis Recherche & Developpement 0,00 €
Servicio Andaluz de Salud 188.946 €
Signatope GmbH 2.254.000 €
Synapse Research Management Partners SL 900.000 €
Tamirna GmbH 1.337.973 €
THE Critical Path Institute (C-Path) NON Profit Corporation 0,00 €
The University of Liverpool 943.125 €
The University of Nottingham 1.018.028 €
Universidad de Malaga 246.452 €
Universidad de Salamanca 69.500 €
Universitaet Bern 45.204 €
Universitat Zurich 2.187.562 €
Universiteit Leiden 3.000,00 €
University of Newcastle Upon Tyne 68.000 €

Quelle: https://cordis.europa.eu/project/id/821283

Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.